A method includes capturing a signal of a detection substrate exposed to a sample containing a target substance; determining that the detection substrate is in a testable state; and generating an assessment of the presence of the target substance in the sample.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

A lateral flow testing device includes a main body adapted to support an element for collecting a sample. The element is supported at a distal end of the testing device and is in fluid communication with one or more testing components having an analyte detection zone for detecting one or more analytes present in said sample. The testing components produce visual information related to said sample, thereby informing the user of the outcome of a test. The device incorporates a handle reconfigurable with respect to said main body such that in a first handle configuration, the handle hinders sight of the visual information to improve privacy of the test, and in a second handle configuration, the handle facilitates the collection of said sample by increasing a distance between a proximal end of the testing device and the element.

Methods and reagents for processing samples for fluorescence analysis. Processing methods include treating samples containing riboflavin to reduce riboflavin-dependent autofluorescence by adding riboflavin binding protein to the sample, irradiating the sample, or a combination thereof. Processing methods also include clarifying samples by coagulating, precipitating, and/or otherwise removing proteins and other components that interfere with fluorescence analysis without removing the analyte. Fluorescence analysis methods include fluorescence polarization analysis (FPA) and others. Reagents suitable for performing the disclosed methods are provided.

A preparation system for preparing a cell suspension having a carrier on which a reactor housing and a magnet system are accommodated, wherein, in the reactor housing, a reaction channel is formed, which extends between an inlet opening arranged centrally on an upper side of the reactor housing and an outlet opening arranged on the outside of the reactor housing and which is bounded by a channel wall, the magnet system being received on the carrier so as to be relatively movable between a first functional position, to bear with a pole face against the channel wall of the reaction channel and a second functional position to assume with the pole face a predetermined distance relative to the channel wall, and having a reactor housing drive for initiating a rotational movement on the reactor housing.

A system for detecting the presence of and/or quantifying the amount or concentration of one or more analytes in a sample includes a flow assay cartridge having a multiplexed sensing membrane that has immunoreaction or biological reaction spots of varying conditions spatially arranged across the surface of the membrane defining an optimized spot map. A reader device is provided that uses a camera to image the multiplexed sensing membrane. Image processing software obtains normalized pixel intensity values of the plurality of immunoreaction or biological reaction spots and which are used as inputs to one or more trained neural networks configured to generate one or more outputs that: (i) quantify the amount or concentration of the one or more analytes in the sample; and/or (ii) indicate the presence of the one or more analytes in the sample; and/or (ii) determines a diagnostic decision or classification of the sample.

Provided is a multiple biomarker simultaneous analysis apparatus comprising: a cartridge mounting portion 210 in which a cartridge 100 is installed, the cartridge 100 including at least one well and a tip 110, wherein the at least one well includes a sample well 101 into which a sample S containing a detection target material T is injected, and a reaction well 105 accommodating a first binding material 105a, which is specifically bound to the detection target material T and to which a marker R is coupled, and the tip 110 is inserted into the at least one well and a second binding material 111 that is specifically bound to the detection target material T is coupled to one end of the tip 110; a tip coupling portion 220 coupled to the tip 110 and movable on a predetermined movement trajectory while being coupled to the tip 110; an optical unit 230 radiating light toward the tip 110 and receiving light generated from the tip 110 according to light radiation; and a processing unit 240 determining whether the detection target material T is present in the sample S according to a predetermined method using the light received by the optical unit 230.

A cell screening device having a bottom plate part; a cell placement membrane provided on the bottom plate part and forming a cell placement surface; a pair of fluid injection parts provided on the bottom plate part and partitioned from the cell placement membrane; and a flow channel provided between the bottom plate part and the cell placement membrane and having flow channel end portions extending to the fluid injection parts. On the cell placement surface of the cell placement membrane are formed a plurality of wells having a size that enables the wells to individually accommodate cells to be screened, and through holes extending from the inner bottom surfaces of the wells and communicating with the flow channel.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.